Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis
Hye Lim Lee(Korea University Medical Center), Byoung Joon Kim(Samsung Medical Center), Seol‐Hee Baek(Korea University Medical Center), Jin Myoung Seok(Samsung Medical Center), Byung‐Jo Kim(Korea University), Sa‐Yoon Kang(Jeju National University), Yeon Hak Chung(Samsung Medical Center), Joong‐Yang Cho(Inje University Ilsan Paik Hospital), Yoon‐Ho Hong(Seoul Metropolitan Government), Jeeyoung Oh(Université Paris-Sud), Sun‐Young Kim(Hanyang Cyber University), Su‐Hyun Kim(National Cancer Center), Sung‐Min Kim(Ulsan College), Sang‐Soo Lee(Chungbuk National University), Juhyeon Kim(Samsung Medical Center), Ju‐Hong Min(Samsung Medical Center), Ho Jin Kim(National Cancer Center), Ha Young Shin(Yonsei University)
Cited by 8
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
A New Subtype Classification of Ischemic Stroke Based on Treatment and Etiologic Mechanism
|European Neurology|2006|121
The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders
|Multiple Sclerosis Journal|2013|84
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea
|Multiple Sclerosis Journal|2017|82